Shlomo K Melmed

6455305, Sep 24, 2002

Jul 23, 1999

08/894251

Shlomo Melmed - Los Angeles CA
Lin Pei - Burlingame CA

Cedars-Sinai Medical Center - Los Angeles CA

C12N 500

435325, 4353201, 435455, 536 231, 536 235, 424 932, 424 9321

Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

6541244, Apr 1, 2003

Jun 7, 1999

09/327138

Christoph J. Auernhammer - Munchen-Pasing, DE
Shlomo Melmed - Los Angeles CA

Cedars-Sinai Medical Center - Los Angeles CA

C12N 1585

4353201, 435455, 435456, 536 231, 536 235, 536 241

Disclosed is a nucleic acid construct comprising a murine SOCS-3 promoter sequence having SEQ. ID. NO. : 1, or a non-murine homologue thereof, or an operative fragment or derivative. The construct can also contain, operatively linked to the SOCS-3 promoter, a gene encoding any preselected protein, and optionally contains a reporter gene to facilitate detection and/or selection of successfully transfected cells. Also disclosed are a transgenic vertebrate cell containing the nucleic acid construct and transgenic non-human vertebrates comprising such cells. The nucleic acid construct is useful in methods of treating a growth retardation or growth acceleration disorder in a human subject and in a method of treating an autoimmune disease, immune disease, or inflammatory condition in a human subject. A kit for genetically modifying a vertebrate cell includes a polynucleotide comprising the murine SOCS-3 promoter sequence is also disclosed.

6673823, Jan 6, 2004

Jun 4, 2002

10/163053

Anthony P. Heaney - Los Angeles CA
Shlomo Melmed - Los Angeles CA

Cedars-Sinai Medical Center - Los Angeles CA

A61K 3144

514369, 569342

Disclosed is a method for treating a pituitary tumor in a mammal, employing the administration of a peroxisome proliferator activated receptor gamma ligand (also known as âperoxisome proliferating-activator receptor gammaâ or âPPAR-â). In some embodiments, the peroxisome proliferator activated receptor gamma ligand is a thiazolidinedione compound. Also disclosed are methods for preventing the formation of a pituitary tumor in a mammal and for preventing the recurrence of a pituitary tumor in a mammal. Further disclosed is a method for treating a mammal exhibiting one or more symptoms of Cushings syndrome.

6723519, Apr 20, 2004

Sep 7, 2001

09/949271

Shlomo Melmed - Los Angeles CA
Lin Pei - Los Angeles CA

Cedars-Sinai Medical Center - Los Angeles CA

G01N 3353

435 71, 435 4, 435 792, 4241301, 4241341, 4241391, 4241411, 4241551

Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in diagnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

6750327, Jun 15, 2004

Sep 7, 2001

09/949476

Shlomo Melmed - Los Angeles CA
Lin Pei - Los Angeles CA

Cedars-Sinai Medical Center - Los Angeles CA

C07K 1600

5303879, 5303871, 5303881, 435 723, 435975

Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

6835380, Dec 28, 2004

Sep 30, 2002

10/261821

Gregory A. Horwitz - Calabasas CA
Xun Zhang - Malden MA
Shlomo Melmed - Los Angeles CA

Cedars-Sinai Medical Center - Los Angeles CA

A61K 39395

4241411, 4241301, 4241341, 4241391, 4241551

Disclosed are isolated antibodies that specifically bind a rat pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C). These antibodies are believed to be particularly useful in connection with methods for inhibiting the neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, whether in vivo or in vitro. This is based on the discovery that PTTG-C molecules have the ability to downregulate pituitary tumor transforming gene (PTTG) expression and/or PTTG function in a dominant negative manner.

6858586, Feb 22, 2005

Apr 29, 2002

10/136082

Gregory A. Horwitz - Calabasas CA, US
Xun Zhang - Malden MA, US
Shlomo Melmed - Los Angeles CA, US

Cedars-Sinai Medical Center - Los Angeles CA

A61K038/00

514 12, 435975, 530300, 530350, 530324

Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a composition containing a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which can be comprised in a chimeric protein, which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated PTTG-C peptides and PTTG-C-containing chimeric proteins are described.

6894031, May 17, 2005

May 12, 2000

09/569956

Gregory A. Horwitz - Calabasas CA, US
Xun Zhang - Malden MA, US
Shlomo Melmed - Los Angeles CA, US

Cedars-Sinai Medical Center - Los Angeles CA

A01N043/04
A01N063/00
C07H021/04
C12N015/63
C12N015/00

514 44, 424 9321, 536 235, 4353201, 435325, 435455, 435810

Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which has the ability to regulate endogenous pituitary, tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG-C-related polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG. Other embodiments are directed to peptide-based treatments that deliver PTTG-C peptide molecules to the cells, which inhibit endogenous PTTG expression and/or PTTG function. Additional embodiments directed to a method of inhibiting tumor angiogenesis, in vivo, are also disclosed. Also disclosed are compositions useful for inhibiting neoplastic cellular proliferation and/or transformation and tumor angiogenesis, including compositions comprising a PTTG carboxy-terminal peptide or comprising a chimeric or fusion protein that contains a first PTTG carboxy-terminal peptide segment and a second cellular uptake-enhancing and/or importation-competent peptide segment.